9th Annual Pharma Pricing, Reimbursement & Market Access 2025
9th Annual Pharma Pricing, Reimbursement & Market Access 2025
7th, 8th & 9th October, 2025
Philadelphia, United States
5 Reasons to attend the event
Knowledge
Gain insights from experts, researchers, and professionals to stay updated on the latest pharma advancements.
An Agenda Made For You
High quality content that addresses your biggest challenges and uncovering hidden opportunities.
Cutting-Edge Insights
Discover the latest trends, innovations, and breakthroughs shaping the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with actionable strategies, real-world case studies, and learn best practices to implement in your work.
Knowledge
Gain insights from experts, researchers, and professionals on the latest pharma advancements.
An Agenda Made For You
High quality content that addresses your biggest challenges and uncovering hidden opportunities.
Cutting-Edge Insights
Explore the latest trends, innovations, and breakthroughs driving the future of the pharmaceutical industry.
Networking
Connect with peers, industry leaders, and collaborators to exchange ideas and explore new opportunities.
Practical Takeaways
Walk away with practical strategies, case studies, and proven best practices to apply in real-time.
Event Speakers
RODNEY E
Sandoz
TOM CROCE
Jazz Pharmaceuticals
BOXIONG TANG
Agenus (Former)
GREG APOSTOL
Alkermes
KAELYN BUCK
Regeneron Pharmaceuticals
SHANTHY K
Johnson & Johnson
DIEGO CORTINA DE LA FUENTE
Biogen
SANKET SHAH
Jazz Pharmaceuticals
CHAKITA W
Bristol Myers Squibb
OMAR ALI
Verpora
EDWARD M
Indivior
DRAKE REITER
Priority Health
ROSS MARGULIES
Manatt Health
ANKA G. E
Merck
HEMANTH K
Recursion
RAHUL S
AstraZeneca
JAMIE GROSSMAN
Bayer
JOAQUIN F. M
CSL Seqirus
DINAKARAN B
Dr. Reddy’s Laboratories
STEPHEN FRAMIL
Merck
RAHUL MITTAL
Dr. Reddy’s Laboratories
IPEK OZER S
Takeda
MICHAEL C
Avalere Health
PETER B
Deallus
CHERYL ROCHE A
UCB
USMAN IQBAL
Julz Pharma
Heather Leigh Flannery
AI MINDSystems Foundation
KELLIE MURPHY
Capricor Therapeutics
AYESHA AZAM
Avalere Health
Download Brochure
Event Schedule
Meet to learn and network with your conference colleagues.
Workshop
THE ART & SCIENCE OF NEGITIATION VALUE BASED AGREEMENTS & INNOVATIVE CONTRACTING
For years, we’ve heard the buzzwords of value-based contracting, risk shares, and outcomes-based agreements. But where are we today? Are the data requirements worth the effort? What have we truly learned? And most importantly, how are they negotiated, deployed & operationalised?
In this executive-level workshop, led by our workshop leaders, we challenge our Pharma Industry community to jointly rethink value-based contracting—the “why” behind the agreements and the journey for how terms are negotiated.
Through this workshop, attendees will re-engineer agreements, challenge assumptions and will have the opportunity to focus on the main theme, that is NEGOTIATION of these innovative contracts.
WORKSHOP LEADERS
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
DRAKE REITER
Director of Pharmacy Operations
Priority Health
Workshop
THE ART & SCIENCE OF NEGITIATION VALUE BASED AGREEMENTS & INNOVATIVE CONTRACTING
For years, we’ve heard the buzzwords of value-based contracting, risk shares, and outcomes-based agreements. But where are we today? Are the data requirements worth the effort? What have
we truly learned? And most importantly, how are they negotiated, deployed & operationalised?
In this executive-level workshop, led by our workshop leaders, we challenge our Pharma Industry community to jointly rethink value-based contracting—the “why” behind the agreements and
the journey for how terms are negotiated.
Through this workshop, attendees will re-engineer agreements, challenge assumptions and will have the opportunity to focus on the main theme, that is NEGOTIATION of these innovative
contracts.
WORKSHOP LEADERS
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
DRAKE REITER
Director of Pharmacy Operations
Priority Health
08:50 - Chairperson opening remarks
Speaker
PETER BARSCHDORFF
Vice President
Deallus
09:00 - KEYNOTE ADDRESS - Medicare/CMS drug price negotiations: Key lessons & recommendations from those who prepared the pharmacuetical manufacturers through all the rounds of negotiations
DRUG PRICE NEGOTIATIONS
Gain the inside track from aformer government payer and a legal firm partner who teamed up to support numerous US pharma Co. in both 1st round & 2nd round CMS/Medicare Drug Price Negotiations.
• Methodology and X-functional support in generation of the ICR submission
• The shift sands of therapeutic alternatives and anchoring price to ceiling price
• How we prepared the teams for the MLS, initial offer rebuttal and subsequent price negotiations
• The makeup and roles of CMS personal, how they changed over the various rounds of negotiations, and when they blow hot and when they blow cold
• What we have learned from new administration and effect of MFN, IRP on the CMS negotiations
• US health plan payer reviewing the implications of MFP medicines effectuation on formulary, 340B issues and access tiers
Speakers
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
DRAKE REITER
Director of Pharmacy Operations
Priority Health
ROSS MARGULIES
Partner & Attorney
Manatt Health
10:20 – Topic TBC
For sponsorship opportunities please contact info.uk@virtueinsight.com
10:50 – Morning Coffee/Tea & Networking
11:20 – Keynote Panel Discussion: Unlocking market access: Winning pricing strategies in pharma
CHALLENGES & OPPORTUNITIES
• Key shifts shaping pharma access globally.
• Aligning pricing with payer, provider, and patient needs.
• Adapting pricing across regions and income levels.
• Innovative Contracting – Exploring risk-sharing and out come-based deals.
• Pricing approaches for access in developing markets.
• Future Outlook: Best practices and trends in access-driven pricing.
• Staying ahead in the race – Update on pricing and market access in USA, EU & RoW
• Implications for companies – What to Prepare for future
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
RODNEY EMERSON
Vice President, Pricing & Contracts
Sandoz
KAELYN BUCK
Senior Director, Government Pricing & Contract Operations
Regeneron Pharmaceuticals
USMAN IQBAL
Chief Medical Officer
Julz Pharma
12:10 – Topic TBC
Speaker TBC, AccessSync
12:40 – Networking luncheon
13:40 – Panel Discussion with experts: Putting patients first: Advancing access through patient-centric innovation
PATIENT ACCESS
• Driving value through tailored approaches
• Patient Insights: Informing pricing and access decisions
• Collaborative Partnerships: Engaging patients and payers
• Value Assessment: Reflecting patient needs in pricing
• Aligning ecosystem by bringing care closer to patients
• Embedding patient feedback in access strategy & capturing patient experience
• Payer-Pharma Collaboration: Ensuring timely access
Moderator
ANKA G. EHRHARDT
Director, Cell-Based Assays / Analytical Research & Development
Merck
Panellists
KELLIE MURPHY
Senior Director, Head of Commercial
Capricor Therapeutics
CHAKITA WILLIAMS
Market Access, Pricing, Value Demonstration Strategy and
Operations Director
Bristol Myers Squibb
RAHUL SHENOLIKAR
Lung Cancer Lead, Oncology Outcomes Research
AstraZeneca
AYESHA AZAM
Associate Principal
Avalere Health
14:30 – The international pricing system
BUSINESS MODELS
• Ideally a pharma company will price “to value” in each individual country. However, the interactions between country prices make this impossible.
• The international pharma-pricing environment viewed as a “system”.
• The counter-intuitive nature of systems and why trying to impose simplicity (by, for example, imposing a ‘ pricing corridor’) is not always appropriate.
• The evolution of international pricing analyses, from in tuition through heuristics to full models.
• What drives parallel trade and the relationship between price differentials, product size etc. and the level of parallel trade?
15:00 – Afternoon Tea/Coffee & Networking
15:30 - The Future of Digital Accessibility in Pharma
TECHNOLOGY – SHAPING THE FUTURE
With January 2025 and the significant change in approaches to equity, inclusion, and belonging, what is the future for Digital Accessibility in Pharma? Explore WHY disability inclusion and accessibility is still important, WHAT Information & Communication Technologies are in scope, and HOW can Inclusive Design be applied across the Pharma digital ecosystem. Relatable, relevant, responsive, responsible!
STEPHEN FRAMIL
Corporate Global Head of Accessibility
Merck
16:00 - Panel Discussion with experts: Technology Impact - Digital Disruption Meets Market Access: Tech’s Role in Shaping the Future of Pricing & Reimbursement
• Empowering physicians as key contributors to access strategies
• Leveraging AI for smarter pricing strategies
• Anticipating payer behavior and market trends through data modeling
• Digital Twins & Simulations: Testing pricing scenarios before launch
• Tech-Enabled Risk Sharing: Monitoring outcomes in real time for value-based contracts
• Automation in Pricing Operations: Streamlining global pricing and compliance processes
• Integrating digital therapeutics into reimbursement frameworks
• Blockchain for transparency for improving pricing integrity and reducing data silos
• Enhancing stakeholder collaboration through digital platforms
• Challenges & Opportunities
Moderator
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
Panellists
RAHUL MITTAL
Head Strategy & Innovation – North America
Dr. Reddy’s Laboratories
16:50 – Chairperson’s closing remarks and end of conference day 02
17:00 – 18:15 – Networking Drinks
08:50 - Chairperson opening remarks
Speaker
PETER BARSCHDORFF
Vice President
Deallus
09:00 - KEYNOTE ADDRESS - Medicare/CMS drug price negotiations: Key lessons & recommendations from those who prepared the pharmacuetical manufacturers through all the rounds of negotiations
DRUG PRICE NEGOTIATIONS
Gain the inside track from aformer government payer and a legal firm partner who teamed up to support numerous US pharma Co. in both 1st round & 2nd round CMS/Medicare Drug Price Negotiations.
• Methodology and X-functional support in generation of the ICR submission
• The shift sands of therapeutic alternatives and anchoring price to ceiling price
• How we prepared the teams for the MLS, initial offer rebuttal and subsequent price negotiations
• The makeup and roles of CMS personal, how they changed over the various rounds of negotiations, and when they blow hot and when they blow cold
• What we have learned from new administration and effect of MFN, IRP on the CMS negotiations
• US health plan payer reviewing the implications of MFP medicines effectuation on formulary, 340B issues and access tiers
Speakers
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
DRAKE REITER
Director of Pharmacy Operations
Priority Health
ROSS MARGULIES
Partner & Attorney
Manatt Health
10:20 – Topic TBC
For sponsorship opportunities please contact info.uk@virtueinsight.com
10:50 – Morning Coffee/Tea & Networking
11:20 – Keynote Panel Discussion: Unlocking market access: Winning pricing strategies in pharma
CHALLENGES & OPPORTUNITIES
• Key shifts shaping pharma access globally.
• Aligning pricing with payer, provider, and patient needs.
• Adapting pricing across regions and income levels.
• Innovative Contracting – Exploring risk-sharing and out come-based deals.
• Pricing approaches for access in developing markets.
• Future Outlook: Best practices and trends in access-driven pricing.
• Staying ahead in the race – Update on pricing and market access in USA, EU & RoW
• Implications for companies – What to Prepare for future
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
RODNEY EMERSON
Vice President, Pricing & Contracts
Sandoz
KAELYN BUCK
Senior Director, Government Pricing & Contract Operations
Regeneron Pharmaceuticals
USMAN IQBAL
Chief Medical Officer
Julz Pharma
12:10 – Topic TBC
Speaker TBC, AccessSync
12:40 – Networking luncheon
13:40 – Panel Discussion with experts: Putting patients first: Advancing access through patient-centric innovation
PATIENT ACCESS
• Driving value through tailored approaches
• Patient Insights: Informing pricing and access decisions
• Collaborative Partnerships: Engaging patients and payers
• Value Assessment: Reflecting patient needs in pricing
• Aligning ecosystem by bringing care closer to patients
• Embedding patient feedback in access strategy & capturing patient experience
• Payer-Pharma Collaboration: Ensuring timely access
Moderator
ANKA G. EHRHARDT
Director, Cell-Based Assays / Analytical Research & Development
Merck
Panellists
KELLIE MURPHY
Senior Director, Head of Commercial
Capricor Therapeutics
CHAKITA WILLIAMS
Market Access, Pricing, Value Demonstration Strategy and
Operations Director
Bristol Myers Squibb
RAHUL SHENOLIKAR
Lung Cancer Lead, Oncology Outcomes Research
AstraZeneca
AYESHA AZAM
Associate Principal
Avalere Health
14:30 – The international pricing system
BUSINESS MODELS
• Ideally a pharma company will price “to value” in each individual country. However, the interactions between country prices make this impossible.
• The international pharma-pricing environment viewed as a “system”.
• The counter-intuitive nature of systems and why trying to impose simplicity (by, for example, imposing a ‘ pricing corridor’) is not always appropriate.
• The evolution of international pricing analyses, from in tuition through heuristics to full models.
• What drives parallel trade and the relationship between price differentials, product size etc. and the level of parallel trade?
15:00 – Afternoon Tea/Coffee & Networking
15:30 - The Future of Digital Accessibility in Pharma
TECHNOLOGY – SHAPING THE FUTURE
With January 2025 and the significant change in approaches to equity, inclusion, and belonging, what is the future for Digital Accessibility in Pharma? Explore WHY disability inclusion and accessibility is still important, WHAT Information & Communication Technologies are in scope, and HOW can Inclusive Design be applied across the Pharma digital ecosystem. Relatable, relevant, responsive, responsible!
STEPHEN FRAMIL
Corporate Global Head of Accessibility
Merck
16:00 - Panel Discussion with experts: Technology Impact - Digital Disruption Meets Market Access: Tech’s Role in Shaping the Future of Pricing & Reimbursement
• Empowering physicians as key contributors to access strategies
• Leveraging AI for smarter pricing strategies
• Anticipating payer behavior and market trends through data modeling
• Digital Twins & Simulations: Testing pricing scenarios before launch
• Tech-Enabled Risk Sharing: Monitoring outcomes in real time for value-based contracts
• Automation in Pricing Operations: Streamlining global pricing and compliance processes
• Integrating digital therapeutics into reimbursement frameworks
• Blockchain for transparency for improving pricing integrity and reducing data silos
• Enhancing stakeholder collaboration through digital platforms
• Challenges & Opportunities
Moderator
HEATHER LEIGH FLANNERY
CEO & Co-Founder
AI MINDSystems Foundation
Panellists
RAHUL MITTAL
Head Strategy & Innovation – North America
Dr. Reddy’s Laboratories
16:50 – Chairperson’s closing remarks and end of conference day 02
17:00 – 18:15 – Networking Drinks
09:20 – Chairperson Opening Remarks
Speaker
PETER BARSCHDORFF
Vice President
Deallus
09:30 – Payer’s perspective – What are they looking for?
PAYER’S PERSPECTIVE
• Embracing payer expectations by introducing them early in product development
• Pricing and reimbursement policies in the light of the financial crisis
• How should be the collaboration with payers?
• Full-filling HTA requirements and demonstrating value to payers
• Understand payer preferences on patient pathway optimization
• Detect and develop solutions to co-create incremental value with external stakeholders including payers
10:10 – New developments and trends of HTA around world
HTA
• New HTA development in EU, US and around the world
• Reimbursement and regulatory agencies are collaborating and bringing value-based decisions.
• Updates of EU’s new HTA Regulation, Joint Clinical As sessment (JCA) utilize the Population, Intervention, Comparator, and Outcome (PICO) framework to define the scope of a health
technology’s evaluation.
• Incorporating market access and HEOR evidence generations into pricing and reimbursement strategy
• Developing successful market access, pricing and reimbursement strategies. Maximize the access of new products to patients.
BOXIONG TANG
AVP Head of HEOR & Medical Value Access
Agenus
10:40 – Morning Coffee/Tea & Networking
11:10 – Keynote Panel Discussion with experts: Capitalizing on Regulatory Developments - New Rules, New Strategies: Finding advantage in changing market
REGULATION OVERVIEW & UPDATE
• Understanding recent global and regional regulatory up dates impacting access
• Legal and regulatory challenges emerging from IRA and state legislation
• Adapting to evolving HTA requirements for faster approvals
• Leveraging transparency regulations to build trust and payer alignment
• Identifying opportunities in faster review pathways and conditional approvals
• Building agile market access plans to keep pace with regulatory shifts
• Collaborating with regulators and payers for early access success
• Using regulatory changes to strengthen value-based con tracting approaches
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
SHANTHY KRISHNARAJAH
Sr. Director, New Products, Patient Engagement Research
Council & IRA
Johnson & Johnson
EDWARD MCADAM
Director, Government Pricing, Contracting Operations and
Analytics
Indivior
MICHAEL CIARAMETARO
Managing Director
Avalere Health
12:00– Solution Provider Presentation
For sponsorship opportunities please contact info.uk@virtueinsight.com
12:30 – Networking luncheon
13:30 – Panel Discussion with experts: From Data to Decisions: Unlocking Market Access with Real-World Evidence
RWE
• Demonstrating real-world effectiveness to support payer decisions
• Enhancing value propositions through real-world out comes data
• Using RWE to complement clinical trial evidence for HTA submissions
• Supporting earlier and broader market access with real-world insights
• Strengthening risk-sharing and outcome-based agreements using RWE
• Driving faster reimbursement through localized real-world data
• Building trust with payers and providers via transparent RWE reporting
• Leveraging RWE to refine patient segmentation and access strategies
• Integrating RWE across the product lifecycle to support sustained access
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
BOXIONG TANG
Former AVP, Head of HEOR & Medical Value Access
Agenus
JAMIE GROSSMAN
National Account Director, HEOR
Bayer
DIEGO CORTINA DE LA FUENTE
Director, Value & Access – Global Value Evidence Strategy
Biogen
SANKET SHAH
Director, Global Value & HEOR
Jazz Pharmaceuticals
HEMANTH KANAKAMEDALA
VP, Decision Science & RWE
Recursion
14:20 – Panel Discussion: Stronger Together: Bridging Industry, Payers, and Patients for Impact
WORKING TOGETHER
• Fostering collaboration across stakeholders to improve patient access
• Building trust and transparency between industry and payers
• Aligning value perceptions between pharma, physicians, and patients
• Enhancing communication channels for more coordinated care
• Integrating patient insights into pricing and reimbursement decisions
• Encouraging early engagement between pharma and HTA bodies
• Driving shared goals through multi-stakeholder partner ships
• Breaking silos to deliver more sustainable, patientcentered outcomes
Moderator
CHERYL ROCHE ALEXANDER
Account Experience Specialist
UCB
Panellists
TOM CROCE
VP Global Patient Advocacy
Jazz Pharmaceuticals
GREG APOSTOL
VP & Head of Market Access
Alkermes
JOAQUIN F. MOULD
Global HEOR & Value Strategy Director
CSL Seqirus
IPEK OZER STILLMAN
Head, Global Health Economics, Payer Value & Patient Access
Takeda
DINAKARAN BALASUBRAMANIAN
Head, Commercial Strategy & Insights, Biologics
Dr. Reddy’s Laboratories
15:10 – Chairperson’s closing remarks and end of conference
15:15 – Afternoon Tea/Coffee & Networking
09:20 – Chairperson Opening Remarks
Speaker
PETER BARSCHDORFF
Vice President
Deallus
09:30 – Payer’s perspective – What are they looking for?
PAYER’S PERSPECTIVE
• Embracing payer expectations by introducing them early in product development
• Pricing and reimbursement policies in the light of the financial crisis
• How should be the collaboration with payers?
• Full-filling HTA requirements and demonstrating value to payers
• Understand payer preferences on patient pathway optimization
• Detect and develop solutions to co-create incremental value with external stakeholders including payers
10:10 – New developments and trends of HTA around world
HTA
• New HTA development in EU, US and around the world
• Reimbursement and regulatory agencies are collaborating and bringing value-based decisions.
• Updates of EU’s new HTA Regulation, Joint Clinical As sessment (JCA) utilize the Population, Intervention, Comparator, and Outcome (PICO) framework to define the scope of a health
technology’s evaluation.
• Incorporating market access and HEOR evidence generations into pricing and reimbursement strategy
• Developing successful market access, pricing and reimbursement strategies. Maximize the access of new products to patients.
BOXIONG TANG
AVP Head of HEOR & Medical Value Access
Agenus
10:40 – Morning Coffee/Tea & Networking
11:10 – Keynote Panel Discussion with experts: Capitalizing on Regulatory Developments - New Rules, New Strategies: Finding advantage in changing market
REGULATION OVERVIEW & UPDATE
• Understanding recent global and regional regulatory up dates impacting access
• Legal and regulatory challenges emerging from IRA and state legislation
• Adapting to evolving HTA requirements for faster approvals
• Leveraging transparency regulations to build trust and payer alignment
• Identifying opportunities in faster review pathways and conditional approvals
• Building agile market access plans to keep pace with regulatory shifts
• Collaborating with regulators and payers for early access success
• Using regulatory changes to strengthen value-based con tracting approaches
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
OMAR ALI
Head of Payers
Verpora (Former Government Payer, Nice HTA)
SHANTHY KRISHNARAJAH
Sr. Director, New Products, Patient Engagement Research
Council & IRA
Johnson & Johnson
EDWARD MCADAM
Director, Government Pricing, Contracting Operations and
Analytics
Indivior
MICHAEL CIARAMETARO
Managing Director
Avalere Health
12:00– Solution Provider Presentation
For sponsorship opportunities please contact info.uk@virtueinsight.com
12:30 – Networking luncheon
13:30 – Panel Discussion with experts: From Data to Decisions: Unlocking Market Access with Real-World Evidence
RWE
• Demonstrating real-world effectiveness to support payer decisions
• Enhancing value propositions through real-world out comes data
• Using RWE to complement clinical trial evidence for HTA submissions
• Supporting earlier and broader market access with real-world insights
• Strengthening risk-sharing and outcome-based agreements using RWE
• Driving faster reimbursement through localized real-world data
• Building trust with payers and providers via transparent RWE reporting
• Leveraging RWE to refine patient segmentation and access strategies
• Integrating RWE across the product lifecycle to support sustained access
Moderator
PETER BARSCHDORFF
Vice President
Deallus
Panellists
BOXIONG TANG
Former AVP, Head of HEOR & Medical Value Access
Agenus
JAMIE GROSSMAN
National Account Director, HEOR
Bayer
DIEGO CORTINA DE LA FUENTE
Director, Value & Access – Global Value Evidence Strategy
Biogen
SANKET SHAH
Director, Global Value & HEOR
Jazz Pharmaceuticals
HEMANTH KANAKAMEDALA
VP, Decision Science & RWE
Recursion
14:20 – Panel Discussion: Stronger Together: Bridging Industry, Payers, and Patients for Impact
WORKING TOGETHER
• Fostering collaboration across stakeholders to improve patient access
• Building trust and transparency between industry and payers
• Aligning value perceptions between pharma, physicians, and patients
• Enhancing communication channels for more coordinated care
• Integrating patient insights into pricing and reimbursement decisions
• Encouraging early engagement between pharma and HTA bodies
• Driving shared goals through multi-stakeholder partner ships
• Breaking silos to deliver more sustainable, patientcentered outcomes
Moderator
CHERYL ROCHE ALEXANDER
Account Experience Specialist
UCB
Panellists
TOM CROCE
VP Global Patient Advocacy
Jazz Pharmaceuticals
GREG APOSTOL
VP & Head of Market Access
Alkermes
JOAQUIN F. MOULD
Global HEOR & Value Strategy Director
CSL Seqirus
IPEK OZER STILLMAN
Head, Global Health Economics, Payer Value & Patient Access
Takeda
DINAKARAN BALASUBRAMANIAN
Head, Commercial Strategy & Insights, Biologics
Dr. Reddy’s Laboratories
15:10 – Chairperson’s closing remarks and end of conference
15:15 – Afternoon Tea/Coffee & Networking
Download Brochure
Venue details
The venue is easily accessible, well-equipped with modern amenities, and offers a comfortable, professional setting for all attendees.
Venue
Philadelphia, USA
Philadelphia,
Pennsylvania,
United States, 19102
+91 000 000 0000
Venue – Phiadelphia, USA
Phiadelphia,
United States
+91 000-000-0000
